News
GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.
A new obesity drug combining four hormones may outperform Wegovy and Mounjaro. Learn what it means for health, science, and investors.
Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...
8h
Investor's Business Daily on MSNHow IBD 50's Hims & Hers Is Shaking Up The Weight-Loss BrawlIn the battle for weight-loss supremacy, Hims & Hers Health has emerged as a dark horse candidate shaking up the market.
While there is still some uncertainty in the market related to tariffs, the U.S. economy, and a new conflict in the Middle ...
Scholar Rock (Nasdaq: SRRK) has unveiled encouraging Phase II data for its experimental therapy apitegromab, showing the drug ...
There is a high demand for weight loss drugs in the US [] A huge surge in Ireland's goods exports in the first quarter of ...
(Reuters) -Current weight-loss methods such as lifestyle changes, surgery, and popular therapies like Novo Nordisk's Wegovy and Eli Lilly's Zepbound result in both fat and muscle loss that can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results